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ABSTRACT OF THESIS 
THE BEHAVIORAL EFFECTS OF FIRST-GENERATION ELECTRONIC 
CIGARETTES AFTER 24-HOUR TOBACCO DEPRIVATION 
Little is currently known about the ability of electronic cigarettes to manage 
tobacco withdrawal symptoms and their abuse liability.  In the current study eight 
conventional cigarette smokers completed nine within-subject study sessions.  In the first 
session participants practiced using an electronic cigarette containing 16 mg/ml of 
nicotine over six 10-puff bouts.  Remaining study sessions were comprised of four two-
day blocks (one for each condition), which assessed measures of tobacco withdrawal 
symptoms and abuse liability following unrestricted cigarette smoking and 24-hour 
tobacco deprivation.  Study conditions included an electronic cigarette with 0, 8, or 16 
mg/ml nicotine concentrations, or preferred brand of conventional cigarette.  Following 
24-hours of tobacco deprivation, smoking conventional cigarettes ameliorated many of 
the self-report and physiological symptoms (decreased heart rate) associated with tobacco 
deprivation, while no attenuation of withdrawal symptoms was indicated following using 
electronic cigarettes, independent of nicotine dose.  On abuse liability measures there 
were no significant changes following using an electronic cigarette (regardless of nicotine 
concentration), while conventional cigarettes engendered significant changes on abuse 
liability measures.  Within the conditions of this study, first-generation electronic 
cigarettes had no measurable efficacy in ameliorating tobacco withdrawal symptoms and 
a reduced abuse liability compared to conventional tobacco cigarettes.  
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CHAPTER ONE: INTRODUCTION TO ELECTRONIC CIGARETTES 
History and Definition 
For decades attempts have been made to develop a nicotine-delivery device that 
provides stimuli similar to that of a tobacco cigarette without the negative aspects of 
inhaling tobacco smoke.  One of the earliest examples of such an attempt can be found in 
a patent filed in 1963 (Gilbert, 1965), which proposed a device that could “provide a safe 
and harmless means for and method of smoking by replacing burning tobacco and paper 
with heated, moist, flavored air.”  Despite this patent, no serious attempt to manufacture 
and distribute such a device was made.  It was not until years later that trials began on 
devices that delivered nicotine via inhalation.  In 1979, Jacobson and colleagues (1979) 
published data demonstrating that serum nicotine levels comparable to those delivered by 
conventional tobacco cigarettes (CC) could be obtained by using a “non-combustible 
cigarette.”  This device did not use combustion or electricity but rather passive diffusion 
of nicotine, embedded in filter paper, into the air as the user inhaled (Dunworth, 2014).  
For a short while this device was manufactured and distributed under the name “Favor,” 
but ultimately failed due to a short shelf life caused by rapid degradation of nicotine into 
a bitter tasting metabolite, cotinine (Dunworth, 2014).  During the 1980’s the major 
tobacco manufacturer R.J. Reynolds was attempting to develop a CC alternative.  While 
R.J. Reynolds filed numerous patents that outlined devices practically indistinguishable 
from current EC’s (e.g. Brooks, Roberts, and Simmons, 1990), no major attempts to 
distribute and manufacture such a device are documented.  The invention of the modern 
EC has been attributed to Chinese pharmacist Hon Lik, who filed a patent in 2004 for a 
“flameless electronic atomizing cigarette” (Lik, 2006).  This patent outlines an 
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electronically powered device that vaporizes a mixture containing, among other things, 
nicotine, glycerol, propylene glycol, and water with an electro-thermal vaporization 
nozzle.  Most modern EC’s still adhere to these basic ingredients and mechanics.  
Although there are similar mechanics and ingredients between EC’s, there are 
many variations in modern EC’s that must be identified when discussing EC’s.  As of 
January 2014, it was estimated that there were at least 466 different brands of electronic 
cigarettes and 7,764 different flavors (Zhu et al., 2014).  Amidst this large variety of 
options, three separable categories of EC’s have emerged: first-, second-, and third-
generation EC’s (Zhu et al., 2014).  First generation EC’s, colloquially referred to as 
“cig-a-likes,” are similar to CC’s in appearance and have relatively low-capacity 
batteries, non-refillable liquid cartridges, few (if any) variable settings, and operate at 
lower wattages.  First generation EC’s typically come in disposable (the entire device is 
discarded once the battery has been depleted or the liquid is gone) or rechargeable (non-
refillable liquid cartridges and the battery can be recharged) variants.  Second-generation 
devices, also known as “eGo” devices, are relatively larger than first-generation devices 
and typically have larger rechargeable batteries, refillable liquid tanks, and some user 
adjustable parameters (e.g. variable voltage).  Third-generation devices, also called 
“mods,” typically have many user-customizable parameters (e.g. voltage or wattage) and 
configurations (e.g. different types of tanks or batteries), and some variants can operate at 
power levels of 100 watts or more. 
Prevalence of Electronic Cigarette Use 
Since the introduction of the modern EC about a decade ago, EC use (vaping) has 
been quickly increasing worldwide.  In the United Kingdom, EC use more than doubled 
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(from 2.7% to 6.7%) between 2010 and 2012 (Dockrell et al., 2013).  Among CC 
smokers in the Czech Republic in 2012, 50% had tried EC’s, while 18.3% used EC’s 
regularly (Kralikova et al., 2013), with 23.5% having ever used an EC and 8.2% having 
used an EC in the past 30 days (Goniewicz and Zielinska-Danch, 2012).  Among men in 
Switzerland between 2010 and 2013, despite a ban on sale of nicotine containing EC’s, 
4.9% had used an EC in the last 12-months (Douptcheva et al., 2013).  Among CC 
smokers in the United States, United Kingdom, Canada, and Australia between 2010 and 
2011, 7.6% had tried EC’s, while 2.9% were current users (Adkison et al., 2013).  In the 
United States the percentage of individuals who were aware of EC’s doubled (from 
16.4% to 32.2%) between 2009 and 2010, while the percentage of individuals who had 
tried EC’s quadrupled (from 0.6% to 2.7%) between 2009 and 2010 (Regan et al., 2013).  
Among young-adults (ages 18-25 years) in the United States who had reported some 
cigarette use (at least once per month), past-month EC use had increased from 6% in 
2009-2010 to 41% in 2013 (Ramo, Young-Wolff, and Prochaska, 2015).  This literature 
yields widely disparate prevalence estimates of EC use, which likely reflects the rapid 
growth of EC use by region and time.  Nonetheless, there is converging evidence for a 
steadily increasing rate of EC use, which underscores the need for further information on 
the behavioral effects of these devices. 
Electronic Cigarettes and Tobacco Withdrawal Symptoms  
Although the health effects of EC’s have not been fully characterized, leaving 
questions about potentially negative effects on the users health (e.g. Goniewicz et al., 
2014), it has been argued that EC’s could be used as a harm reduction tool for current CC 
smokers (for review see Farsalinos and Polosa, 2014).  Although evidence showing 
4 
efficacy of EC’s as smoking cessation devices is limited, a recent meta-analysis has 
shown that EC use is associated with a reduction in CC smoking (Rahman et al., 2015).  
As a smoking cessation tool, EC’s might be able to diminish CC smoking withdrawal 
symptoms and reduce smoking relapse rates among individuals who are current CC 
smokers. 
The withdrawal effects of CC’s have been well characterized.  Tobacco 
withdrawal has been generally defined as “a syndrome of behavioral, affective, cognitive, 
and physiological symptoms, typically transient, emerging upon cessation or reduction of 
tobacco use, and causing distress or impairment” (Shiffman, West, and Gilbert, 2004).  
Within 24-hours of abstinence from tobacco, individuals typically report increased levels 
of craving for tobacco, increase in negative affective states (e.g. feeling angry, impatient, 
anxious, or depressed) (Hughes, 2006; Piper et al., 2011), impaired cognition (Heishman, 
Taylor, and Henningfield, 1994; Shiffman, West, and Gilbert, 2004; Swan and Lessov-
Schlaggar, 2007; Heishman et al., 2010), and decreased heart rate (Hughes, 1992).  To 
date, there are only a small number of laboratory studies that have examined the ability of 
EC’s to alleviate the aforementioned withdrawal symptoms.  In a study by Bullen and 
colleagues (2010), following a 12-hour tobacco deprivation period, EC naïve CC smokers 
were allowed ad libitum access to a first-generation EC with 0 or 16 mg/ml nicotine 
concentration.  Following using an EC with 0 or 16 mg/ml nicotine concentrations, 
participants reported reductions in negative affective states (i.e. irritability, restlessness, 
and difficulty concentrating) and cravings to smoke independent of nicotine 
concentrations, but to a lesser degree than following smoking a CC.  In a study by 
Vansickel and colleagues (2010), EC naïve CC smokers who refrained from smoking for 
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12 hours administered 10-puffs from first-generation EC’s that contained liquid with 16 
or 18 mg/ml nicotine concentration, which significantly reduced cravings for smoking 
compared to baseline, though the reductions in cravings were less than those following 
smoking a CC.  In another study by Vansickel and colleagues (2012), following a 12-
hour tobacco deprivation period, EC naïve CC smokers administered six 10-puff bouts 
from a first-generation EC with 18 mg/ml nicotine concentration with 30-minutes 
between bouts, after which increases in heart rate and decreases in reported craving for 
smoking and negative affective states (e.g. anxiousness, restlessness, and 
irritability/frustration/anger) were reported.  In a third study by Vansickel and Eissenberg 
(2013), regular EC users with minimal current CC use (< 5 cigarettes/day) administered 
10-puffs from their own EC’s (typically containing 18 mg/ml nicotine concentration) 
following a 12 hour EC and CC deprivation period.  After administration of 10-puffs 
there were decreases in negative affective states (i.e. “anxious,” “restlessness”), cravings 
for smoking and intentions to smoke, and an increase in heart rate relative to levels prior 
to EC use.  In a study by Dawkins and colleagues (2012), following a 1-hour CC 
deprivation period, EC naïve CC smokers used a first-generation EC containing 0 or 16 
mg/ml nicotine concentration ad libitum for a five-minute period.  Following EC use, 
there were decreases in some negative affective states (contingent upon being male or 
female) in both 0 and 16 mg/ml nicotine concentration conditions vs. just holding an EC.  
Similarly, there were mixed effects on cognitive functioning with individuals in the 0 
mg/ml condition making fewer errors on an attention task relative to individuals who just 
held an EC, and individuals in the 16 mg/ml condition making fewer recall errors on a 
memory task compared to individuals who just held an EC.  In another study by Dawkins 
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and colleagues (2013), following 12-hours of tobacco deprivation, CC smokers used a 
second-generation EC containing 0 or 16 mg/ml nicotine concentration ad-libitum for 10 
minutes.  Compared to the 0 mg/ml condition, individuals performed better on a 
prospective memory task and reported greater reductions in negative affective state (i.e. 
anxiousness) and cravings to smoke after using an EC with 16 mg/ml nicotine 
concentration.  In a study by Yan and D’Ruiz (2015), following 36-hours of tobacco 
deprivation regular CC smokers took 50-puffs from a first-generation EC containing 16 
or 24 mg/ml nicotine concentration, followed by ad-libitum EC use for one hour.  After 
taking 50-puffs and ad-libitum EC use, dose-related increases in heart rate were shown 
following EC use, with increases after using an EC with 24 mg/ml nicotine 
concentrations that were comparable to increases following smoking a CC.  In a study by 
Lechner and colleagues (2015), following a 12-hour tobacco deprivation period regular 
CC smokers with minimal EC use were given five minutes of ad-libitum access to a first- 
or second-generation EC containing 16 mg/ml nicotine concentration.  Following use, 
both first- and second-generation EC’s reduced negative affective states and cravings to 
smoke, with greater reductions following second-generation EC’s compared to first-
generation EC’s.  Using a slightly different design than the previous studies, Norton and 
colleagues (2014) allowed a group of regular CC smokers to use a first-generation EC 
with 11 mg/ml nicotine concentration in lieu of a CC over a 72-hour period.  After the 
72-hour period, withdrawal symptoms were not significantly different than baseline 
levels.  It is difficult, however, to interpret this finding because many individuals in this 
study did not successfully abstain from CC use during the 72-hour period, and there were 
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no other comparison conditions during the 72-hour period (e.g. abstinence from EC or 
CC use). 
The aforementioned studies suggest that EC’s can ameliorate some CC 
withdrawal symptoms, but typically to a lesser extent than CC’s.  Yet, there are several 
limitations to these studies that make interpreting their results difficult.  One limitation is 
that all but one (Norton et al., 2014) of the previous studies did not collect pre-
deprivation levels of the withdrawal symptoms and only collected measures immediately 
prior to using an EC.  While previous characterizations of withdrawal can help to identify 
typical withdrawal symptoms, pre-deprivation measurements are required to validate the 
presence of a true withdrawal symptom.  In recognition of this problem, Shiffman and 
colleagues (2004) suggest that stable baseline levels of candidate withdrawal symptoms 
be collected across multiple sessions, following unrestricted smoking, in order to obtain 
stable baseline levels of withdrawal symptoms.  Then, pre-deprivation measurements can 
be used to determine true withdrawal symptoms as those that have changed relative to 
baseline levels following a deprivation period. 
There is ambiguity in the literature as to when exactly tobacco withdrawal 
symptoms emerge.  Most studies that have examined tobacco withdrawal symptoms have 
assessed post-smoking levels 24-hours or more since the beginning of tobacco 
deprivation (for review see Hughes, 2006).  Thus, it is unclear when exactly withdrawal 
symptoms begin within 24-hours of tobacco deprivation.  There is, however, evidence 
that some withdrawal symptoms (e.g. craving for smoking and heart rate) begin to 
manifest within 30 minutes following smoking (Hendricks et al., 2006).  This might 
suggest that the ideal time to measure craving for smoking is immediately following the 
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last tobacco administration preceding a tobacco deprivation period.  Yet, on other 
measures, acute smoking effects could confound measurements taken immediately after 
smoking.  For example, there are well-characterized acute smoking effects on cognitive 
performance measures (Heishman, Kleykamp, and Singleton, 2010).  Additionally, it has 
been shown that some self-report measures of tobacco withdrawal symptoms (e.g. 
difficulty concentrating, anxiety, sadness) do not begin to appear until at least 30-minutes 
following smoking (Hendricks et al., 2006).  In recognition of the ambiguity of 
withdrawal symptom time course, measures in the current study were collected following 
ad libitum smoking conditions and immediately following smoking on baseline days.  
These data were used to help interpret the effects of smoking conditions on performance 
following tobacco deprivation.    
Another limitation in the literature on alleviation of tobacco withdrawal 
symptoms by EC’s is that none of the aforementioned studies examined different 
concentrations of nicotine within the same device, and selected only one nicotine 
concentration and compared it to an EC with 0 mg/ml.  Thus, it remains uncertain 
whether there is a dose-dependent relationship between nicotine concentration in EC’s 
and their ability to ameliorate tobacco withdrawal symptoms.  A final limitation is that 
the aforementioned studies typically used short deprivation periods (e.g. 1-12 hours of 
deprivation from tobacco).  Although some tobacco withdrawal symptoms may occur 
soon after smoking, some may take longer to develop (as discussed in Hughes, 1992).  
Therefore, a longer period of tobacco deprivation may be required to examine some 
withdrawal symptoms.     
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Abuse Liability of Electronic Cigarettes 
Little is currently known about the abuse liability of EC’s.  Abuse liability can be 
defined as the ability of a substance to act as a reinforcer or to elicit pleasurable mood 
states (Jasinski, Johnson, and Henningfield, 1984).  Ability of an EC to alleviate tobacco 
withdrawal symptoms would likely contribute to its reinforcing efficacy.  That is, if EC’s 
were able to effectively alleviate aversive withdrawal symptoms, it could be predicted 
that they would have some degree of abuse liability when used in the presence of CC 
withdrawal symptoms.  As such, the findings discussed in the previous section would 
suggest that EC’s might have some abuse liability among CC smokers who are 
experiencing withdrawal symptoms.   
Another way of assessing reinforcing efficacy is to use a choice procedure 
between an EC and another known reinforcer.  To date, only one study has used this 
method.  Vansickel and colleagues (2013) compared EC’s to money, among regular CC 
smokers following 12 hours of CC abstinence, and found an average crossover value (the 
point that participants would choose money over 10 puffs of EC or CC) of $1.06 for first-
generation EC’s with 16 mg/ml vs. $1.50 for CC’s.  This suggests that EC’s might have 
some abuse liability, but relatively less than CC’s.  Another method of assessing abuse 
liability is to measure drug liking with subjective effects measures (e.g. visual analog 
scales or Likert scales).  Although ratings of drug liking do not account for a variety of 
other factors that might influence abuse liability of a drug (e.g. societal views of using the 
drug, known health risks, availability), this is considered an important aspect to the abuse 
liability of a drug (discussed further in Jasinski and Henningfield, 1989).  Although scant, 
there are a few studies that have assessed liking of EC’s in controlled laboratory studies.  
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In two separate studies, increases in measures associated with liking (i.e. ‘pleasant,’ 
satisfying,’ taste good’) were observed following administration of participants’ own EC 
compared to levels prior to EC use (Vansickel and Eissenberg, 2012, Vansickel, Weaver, 
and Eissenberg, 2013).  In an earlier study by Vansickel and colleagues (2010) 
participants rated first generation EC’s with 16 or 18 mg/ml nicotine concentration 
significantly lower than CC’s on measures of liking (i.e. ‘satisfying,’ ‘pleasant’), 
suggesting a lower abuse liability for EC’s compared to CC’s.  In a study comparing first 
generation EC’s with 0 or 16 mg/ml nicotine concentrations, EC’s with 16 mg/ml were 
rated higher on measures of liking (i.e. ‘pleasant to use’) compared to EC’s with 0 mg/ml 
(Bullen et al., 2010), suggesting that presence of nicotine in an EC contributes to their 
abuse liability.  This is congruent with research demonstrating nicotine dose-dependent 
relationships in abuse liability of CC’s (Henningfield, Miyasato, and Jasinski, 1985).  In a 
study comparing first-generation EC’s with 18 mg/ml nicotine concentrations among 
regular EC smokers, participants endorsed “satisfaction” following EC use (Dawkins and 
Corcoran, 2014).  In a study examining EC use over 72-hours, first-generation EC’s with 
11 mg/ml nicotine concentrations were rated less ‘satisfying’ than CC’s (Norton, June, 
and O’Connor, 2014).  In a study comparing the effects of first- and second-generation 
EC’s with 18 mg/ml nicotine concentrations among regular EC users, greater ratings of 
‘satisfying’ were reported following second-generation EC’s compared to first-generation 
EC’s (Farsalinos et al., 2014).  This suggests that the specific type of EC being used 
contributes to the abuse liability of EC’s.   
Although the aforementioned studies provide some evidence for the abuse 
liability of EC’s, there are several limitations that must be acknowledged.  It has been 
11 
suggested that in order to effectively assess abuse liability, the drug under consideration 
should be administered in at least two different dosages, with placebo and positive 
control conditions for comparison (Jasinski and Henningfield, 1989).  Although the abuse 
liability of an EC may represent factors beyond nicotine (e.g. visual and tactile stimuli 
associated with handling and inhaling vapor from these devices), nicotine likely 
constitutes a major contributor to the abuse liability of EC’s (evidenced by Bullen et al., 
2010).  If this is the case, the fact that none of the aforementioned studies utilized a 
meaningful range of nicotine dose concentrations is a limitation on the research of abuse 
liability of EC’s thus far.  Additionally, some of these studies did not utilize a placebo 
condition or some type of positive control condition (i.e. a CC), making quantification of 
abuse liability difficult.  As such, further research on the effects of multiple doses of 
nicotine and their relative effects compared to placebo and control conditions may better 
characterize the abuse liability of EC’s.   
Public opinion is divided on whether EC’s could serve as a useful smoking 
cessation tool for CC smokers, or whether they pose an additional risk to public health. 
This reflects the lack of consensus on the health effects (for review see Callahan-Lyon, 
2014) and abuse liability (for review see Evans and Hoffman, 2014) of these devices.  In 
order for current or future users of EC’s and public health officials to make informed 
decisions about EC use in the future, further research is required on both these issues.  In 
order to provide information on the abuse liability and ability of EC’s to alleviate 
withdrawal symptoms engendered by CC deprivation in individuals with minimal EC 
experience, a research study that examines the physiological, subjective, and cognitive 
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effects of multiple nicotine concentrations of EC’s, on CC smokers deprived of tobacco 
for 24 hours, was conducted.   
13 
CHAPTER TWO: METHODS 
Participants 
Eight healthy adults (2 females), between 22 and 47 years of age, were recruited 
with online advertisements and flyers placed in the local community.  Individuals 
responding to advertisements completed a telephone interview or Internet-based 
questionnaire comprised of questions about general health status and tobacco and 
electronic cigarette use history.  Sample size was chosen based on previous abuse liability 
studies with similar designs (e.g. Vansickel and Eissenberg, 2012; Henningfield, 
Miyasato, and Jasinski, 1985; Babalonis et al., 2013).  Individuals who met study criteria 
over the phone or Internet were invited into the lab for a screening visit.  Screening visits 
consisted of a battery of medical and psychological questionnaires including the 
Structured Clinical Interview for DSM-IV (SCID), one-year timeline follow-back for CC 
use, Fagerstrom test for nicotine dependence, a drug-use history questionnaire, and blood 
chemistry, liver function, and urinalysis tests.  To be eligible to participate participants 
had to report smoking an average of 10 or more tobacco cigarettes per day for at least 
one-year, and not report being a regular electronic cigarette user (defined as daily use of 
an EC for the past seven-days).  Individuals were excluded if they had a history of 
significant medical illness (e.g., cardiovascular disease, neurological or psychiatric 
disorder), were currently pregnant or breastfeeding, or had any other condition that would 
increase risk for study participation.  Each participant’s screening information was 
examined and approved by a study physician before beginning study procedures.  A total 
of eight volunteers initiated the study and all eight completed.  The University of 
Kentucky’s Institutional Review Board approved all study procedures.   
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Design 
The study consisted of an initial practice day and four two-day blocks each 
comprised of two sessions occurring over two consecutive days.  All sessions typically 
occurred at the same time each day.  Baseline sessions were incorporated to capture 
measurements of participants following typical tobacco use behaviors, while deprivation 
days were used to measure changes from baseline following 24-hour tobacco deprivation, 
and relative changes following use of an EC or CC.  A placebo-controlled, randomized 
within-subjects design was used to examine the behavioral effects of nicotine 
concentrations distributed by an EC on deprivation days.  Treatment conditions consisted 
of smoking a preferred (i.e., own) brand cigarette (not blinded) or puffing from an EC 
delivering vapor from liquid with nicotine concentrations of 0, 8, or 16 mg/ml under 
double-blind conditions.  
Schedule 
Practice Day 
Previous research has suggested that in order to effectively acquire nicotine from 
an EC, naïve users must be sufficiently practiced with use of an EC (Vansickel and 
Eiseenberg, 2012).  In order to assure sufficient practice with the EC, and familiarity with 
study procedures, following 24-hours of tobacco deprivation all study participants 
completed a six-session practice day.  During each session participants took ten puffs 
from an EC delivering vapor from liquid with 16 mg/ml nicotine concentration using a 
paced puffing procedure, described below, for a total of 60 puffs over the entire practice 
day.  There were 30-minutes between each session and assessments measures were 
completed before and after each puffing bout to familiarize participants with the 
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measures.  These data were collected but not analyzed due to possible practice and carry-
over effects from the last nicotine administration. 
Baseline and Deprivation Days 
Participants were instructed to abstain from solid food and caffeine four hours 
prior to each session.  Participants were provided with a standard fat- and caffeine-free 
snack shortly after arrival.  Sessions lasted approximately one hour.  At the start of every 
session participants completed field sobriety, breath (Alcohol Sensor III, Intoximeters, 
Inc.; piCO Carbon Monoxide Monitor, Bedfont Scientific), and urine tests (cocaine, 
benzodiazepine, barbiturate, marijuana, amphetamine, and opiate drug use using OnTrak 
TestStik, Varian, Inc.; pregnancy using Clearview HCG II, Unipath, Ltd).  During CC 
and EC use participants were cued by a laptop computer to take 10 two-second puffs, 
with 30-second inter-puff intervals.  Both CC’s and EC’s were inhaled through a 
mouthpiece connected to a volumetric transducer in order to verify whether the 
participant was inhaling in accordance to the puffing procedure.  Since the volumetric 
transducer was not calibrated for an EC, these data were collected but not analyzed.  Use 
of the volumetric transducer, however, did not impede or restrict inhalation of the EC or 
CC in any way.   
Baseline and deprivation days in two-day blocks occurred on consecutive days 
with at least 48 hours separating each two-day block.  During each session, assessment 
measures were completed approximately 20-minutes after arrival (immediately preceding 
EC or CC use), and immediately after EC or CC use.  On baseline days, following 
unrestricted smoking prior to arriving at the lab, a non-blinded CC of the participants 
preferred brand was administered using the paced puffing procedure.  On deprivation 
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days, following 24-hours of tobacco and nicotine deprivation (as verified by CO levels ≤ 
6 ppm or 10% of their CO level from the previous baseline day [whichever was higher]), 
participants completed cognitive tasks and self-report questionnaires before and after 
using a single CC of their preferred brand (baseline and deprivation days), or EC 
containing liquid with a nicotine concentration of 0, 8, or 16 mg/ml (deprivation days).  
Assessments and Tasks 
Minnesota Nicotine Withdrawal Scale (MNWS)(Hughes and Hatsukami, 1986; 
Hughes and Hatsukami, 2008): Thirteen items from the MNWS were used to examine 
effects of tobacco deprivation and alleviation from withdrawal symptoms after CC or EC 
use.  Two questions associated with sleep (i.e. “insomnia, sleep problems, awakening at 
night” and “dreaming or nightmares”) were not used.  Participants rated the following 
items on an ordinal scale ranging from 0 (“none”) to 4 (“severe”): “angry, irritable, 
frustrated,” “anxious or nervous,” depressed mood or sad,” desire or craving to smoke,” 
difficulty concentrating,” “increased appetite, hungry or weight gain,” “restless,” 
“impatient,” “constipated,” “dizziness,” “coughing,” “nauseous,” and “sore throat.”  
Questionnaire Smoking Urges-Brief (QSU-B)(Cox, Tiffany, and Christen, 2001): 
This brief 10-item questionnaire assesses desire to smoke and anticipated relief from 
negative affect by EC or CC use.  Responses are submitted by using a 100-point sliding 
scale anchored on the left by “not at all” and on the right by “extremely.”  Previous 
research has indicated that this scale is sensitive to CC withdrawal effects (West and 
Ussher, 2009).   
Visual Analog Scale – Smoking Effects (VAS-SE)(Blank, Sams, Weaver, and 
Eissenberg, 2008): the VAS-SE is comprised of ten items that have been shown to be 
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sensitive to the effects of nicotine.  Participants were asked to rate their current feelings 
related to each item by placing a mark on a 100-unit line with the left endpoint of this 
continuum labeled “Not at all” and the right endpoint labeled “Extremely.”  Items on the 
VAS-SE included the following: “confused,” “dizzy,” “headache,” “heart pounding,” 
“light-headed,” “nausea,” “nervous,” “salivation,” “sweaty,” and “weak.”   
Visual Analog Scale – Post Smoking (VAS-PS): Six items were used to assess the 
effects of using an EC or CC.  Participants were asked to rate their current feelings 
related to each item by placing a mark on a 100-unit line with the left endpoint of this 
continuum labeled “Not at all” and the right endpoint labeled “Extremely.”  Items on the 
VAS-PS included the following: “stimulated,” “like the effects,” “want to smoke again,” 
“enjoy the e-cigarette,” “crave the e-cigarette,” and “get pleasure from the e-cigarette?”  
Digit-Symbol Substitution Task (DSST): Participants completed a two-minute 
computerized version of the DSST (McLeod, Griffiths, Bigelow, and Yingling, 1982).  In 
this revised task a digit-symbol code, consisting of geometric patterns associated with 
numbers 1-9, is constantly displayed at the top of the screen.  The geometric patterns are 
comprised of 9 white and black boxes in 3x3 rows and columns that correspond to 
buttons on a 9-key keypad.  In the center of the screen a random test digit 1-9 is 
displayed.  Participants are asked to replicate the geometric pattern at the top of the 
screen associated with the test digit by pressing keys in a top-to-bottom order on a 9-key 
keypad.  The test digit changes after the participant has pressed at least one key for each 
of the three rows.  Participants are given visual feedback after each key press to indicate 
whether they pressed the correct or incorrect key.  The DSST has been shown to be 
sensitive to nicotine deprivation (Pickworth et al., 1996).  Two outcome measures from 
18 
this task were examined, total number of trials completed and percentage of trials 
completed that were correct.   
Rapid Information Processing Task (RIP)(Fillmore, Marczinski, and Bowman, 
2005): Participants completed a 5-min computerized version of the rapid information-
processing task.  During this task single digits were presented on-screen at a rate of 90 
digits/min.  Participants were instructed to press a key whenever three consecutive odd or 
even digits were presented.  Initially, each digit was displayed on-screen for 67 ms with 
an ISI of 600 ms.  Based on performance, the presentation rate increased (after correct 
responses) or decreased (after incorrect responses).  Previous research has shown that 
RIP performance is sensitive to CC nicotine yield in regular tobacco smokers who have 
undergone smoking deprivation (Wesnes and Warburton, 1984).  Four outcome measures 
from this task were examined: average digit rate, reaction time to correctly identified 
sequences (hits), percentage of sequences correctly identified (proportion correct), and 
number of responses when a sequence was not present (commission errors). 
Cardiovascular Measures: Heart rate and blood pressure were recorded using an 
automated blood pressure monitor (Dinamap Pro 200, General Electric) before and after 
each EC or CC use.  Measurements were taken while the participant was seated and took 
approximately 60-seconds.  Diastolic and systolic blood pressure were consolidated into 
estimated mean arterial pressure (MAP) by using the following equation:  
𝑀𝐴𝑃 =   
𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 + 2  (𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐)
3
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Drug 
The Blu® (Lorillard Technologies, Inc; Greensboro, NC) rechargeable EC was 
used for this study.  This EC was chosen as a representative of first generation EC’s 
because of its wide availability throughout the United States.  The white and tan colored 
Blu® EC with “Classic Tobacco” liquid flavoring was used to best approximate a CC.  
Liquid tanks offered by the manufacturer with varying nicotine concentration (i.e. “none” 
0 mg/ml, “low” 6-8 mg/ml, and “high” 14-16 mg/ml) were used to experimentally 
manipulate nicotine concentrations.  Each disposable liquid tank was used for a 
maximum of four 10-puff sessions.  Participants’ preferred brand of CC was supplied for 
own brand (OB) conditions.  Adherence to the paced puffing procedure was verified via 
video cameras and a volumetric transducer that tracked puffing behavior.  
Data Analysis 
To examine smoking on baseline days separate mixed models were fit for all 
variables, except VAS-PS variables, with session (pre-smoking on baseline days and 
post-smoking on baseline days) as the independent variable.  To examine tobacco 
deprivation effects, two separate analyses were conducted. To examine the difference 
between unrestricted smoking and 24-hour tobacco deprivation separate mixed models 
were fit for all variables, except VAS-PS variables, with session (analysis 1: pre-smoking 
on baseline days and prior to EC or CC use on deprivation days; analysis 2: post-smoking 
on baseline days and prior to EC or CC use on deprivation days) as an independent 
variable.  Differences between the aforementioned time points were evaluated for 
statistical significance by using t-tests to compare the least squares means derived by 
each mixed model.  To examine acute EC or CC effects according to condition, a mixed 
20 
model was fit on withdrawal and acute effects measures with ratings following EC or CC 
use on deprivation days as the dependent variable, condition (own brand cigarette or EC 
with 0, 8 or 16 mg/ml of nicotine) as an independent variable, and ratings prior to EC or 
CC use on deprivation days as a covariate.  When significant effects of condition were 
indicated, post-hoc pairwise comparisons of least-square means of each condition were 
conducted.  To determine whether there were significant changes on withdrawal 
associated measures (i.e. RIP, DSST, MNWS, QSU-B, and HR and blood pressure) based 
on condition, a mixed model was fit on the difference between measures preceding and 
following EC or CC use on deprivation days with dose as the independent variable.  
When a significant effect of dose was indicated in these models t-tests were conducted 
for each condition to determine whether the difference between measures preceding or 
following EC or CC use was significantly different from 0.  Hochberg’s step-up 
procedure (Hochberg, 1988) was used to control error rates for each family of pairwise 
comparisons.  Mixed models were fit using PROC MIXED in the SAS statistical software 
package, version 9.3 (SAS Institute Inc., Cary, NC).  The alpha level for all analyses was 
set at 0.05.  
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CHAPTER THREE: RESULTS 
Demographic and Clinical Variables: 
Demographic and clinical variables are summarized in Table 3a.  Participants 
were primarily Caucasian (87.5%) and male (75%), smoked an average of 19.7 ± 9.4 
cigarettes per day, and had an average score of 5.6 on the FTND.  Minimal alcohol use 
was reported, with all participants reporting some use at an average frequency of less 
than one day per week.  Participants reported minimal marijuana use, with five non-users 
and three users reporting an average of 2.3 occasions per month.   
Carbon monoxide levels decreased from an average of 29.0 ppm (SD=18.3) prior 
to smoking on baseline days, to an average of 5.5 ppm (SD=1.6) following 24 hours of 
tobacco deprivation.  Average pre- and post-deprivation carbon monoxide levels for each 
participant are displayed in Table 3d.  
Effects of OB smoking on baseline days (under column ‘baseline smoking’), 24-
hour tobacco deprivation (under column ‘24-Dep’), and measures following OB or EC 
use relative to measures prior to use (following 24-hr deprivation), are summarized in 
Table 3b.  Direct comparisons between OB and EC use conditions are summarized in 
Table 3c. 
RIP: 
Baseline Smoking and Deprivation Effects: There were no significant changes in 
digit presentation rate, reaction time on correct trials, proportion correct, or commission 
errors after smoking OB on baseline days.  Digit rate on the RIP significantly increased 
[t(7)=4.76, p=.002] from 90.7 digits per minute after smoking on baseline days to 98.8 
digits per minute after 24-hours of tobacco deprivation; this rate was not significantly 
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different from pre-smoking rate on baseline days (Figure 3a).  Reaction time on correct 
trials significantly decreased [i.e., improved, t(7)=3.49, p=.01] after tobacco deprivation 
from 346.5 ms after smoking on baseline days to 323.2 ms after 24-hours of tobacco 
deprivation; this time was not significantly different from the pre-smoking reaction time 
on baseline days.  Proportion correct on the RIP significantly increased [t(7)=4.15, 
p=.004] from 55.8% correct after smoking on baseline days to 61.6% correct after 24-
hours of tobacco deprivation; this rate was not significantly different from pre-smoking 
rate on baseline days. 
Post-Deprivation OB or EC Effects: There were no significant changes in RIP 
task performance after OB or EC conditions.  
DSST:  
Baseline Smoking and Deprivation Effects: On baseline days, total trials 
completed during the two-minute DSST significantly increased [t(7)=2.37, p=.05] from 
56.2 trials to 58.6 trials after smoking OB.  After 24-hours of tobacco deprivation total 
trials completed significantly decreased [t(7)=3.22, p=.01] from 58.6 to 54.9 trials 
(Figure 3b), though 54.9 trials was not significantly different from trials completed pre-
smoking on baseline days.   
Post-Deprivation OB or EC Effects: A main effect of condition was observed on 
total trials completed [F(3, 21)=3.18, p=.05], with significantly more trials completed 
following using OB [t(21)=2.85, p=.01] and EC with nicotine levels of  8 mg/ml 
[t(21)=3.11, p=.005] compared to pre-smoking on deprivation days (Figure 3b).  Based 
on the data presented in Figure 3b, which was counterintuitive to the statistical finding of 
significantly more trials completed following 8 mg/ml, a follow-up analysis of 
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performance measures prior to OB or EC use on deprivation days was conducted.  This 
revealed a main effect of condition prior to OB or EC use [F(3, 21)=7.56, p=.001], with 
significantly fewer trials completed prior to 8 mg/ml compared to the 0 and 16 mg/ml 
conditions.  
VAS-Smoking Effects:  
Baseline Smoking and Deprivation Effects: On baseline days, ratings of ‘dizzy’ 
on the 100-point VAS scale significantly increased [t(7)=2.41, p=.05] from 0.3 to 4.0 
after smoking OB.  Ratings of ‘heart pounding’ significantly increased [t(7)=3.05, p=.02] 
from 0.3 to 4.3 after smoking OB and significantly decreased [t(7)=2.93, p=.01] from 4.3 
to 0.5 following 24-hours of tobacco deprivation, though 0.5 was not significantly 
different from pre-smoking ratings on baseline days.  On baseline days, ratings of 
‘lightheaded’ significantly increased [t(7)=3.62, p=.009] from 0.2 to 6.0 after smoking 
OB and significantly decreased [t(7)=3.59, p=.009] from 6.0 to 0.2 after 24-hours of 
tobacco deprivation; 0.2 was not significantly different from pre-smoking ratings on 
baseline days. 
Post-Deprivation OB or EC Effects: On deprivation days, a main effect of 
condition was observed on change in feeling ‘lightheaded’ after OB or EC use [F(3, 
21)=8.90, p<.001], with significantly higher ratings following smoking OB [t(21)=4.31, 
p<.001] compared to pre-smoking.  A relative difference between conditions was 
indicated on feeling ‘lightheaded’ [F(3, 20)=7.49, p<.002], with significantly higher 
ratings of feeling ‘lightheaded’ following OB (19.1) compared to EC nicotine levels of  0 
(0.8), 8 (2.8), or 16 mg/ml (0.9). 
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MNWS: 
Baseline Smoking and Deprivation Effects: On baseline days, ratings of ‘desire or 
craving to smoke’ on the five-point MNWS significantly decreased [t(7)=6.94, p<.001] 
from 1.8 to 0.5, ratings of ‘dizziness’ significantly increased [t(7)=2.85, p=.03] from 0 to 
0.3 and ratings of ‘sore throat’ significantly increased [t(7)=3.12, p=.02] from 0 to 0.2 
after smoking OB.  Ratings on eight of the 13 MNWS items (i.e. feeling ‘angry, irritable, 
or frustrated,’ ‘depressed mood or sad,’ ‘desire or craving to smoke,’ ‘difficulty 
concentrating,’ ‘increased appetite, hungry, or weight gain,’ ‘restless,’ ‘impatient’) 
significantly increased from post-smoking on baseline days to after tobacco deprivation, 
with levels all exceeding those reported pre-smoking on baseline days.  Ratings on three 
of the 14 MNWS items (i.e. feeling ‘dizziness,’ ‘coughing,’ ‘sore throat’) significantly 
decreased after tobacco deprivation, although they did not decrease below levels reported 
pre-smoking on baseline days.  Total Scores on the MNWS ranged from 0-52 and 
significantly increased [t(7)=5.48, p<.001] from 2.3 to 7.2 after 24-hours of tobacco 
deprivation, which exceeded levels reported pre-smoking on baseline days. 
Post-Deprivation OB or EC Effects: On deprivation days, a main effect of 
condition was observed on change in rating of ‘desire or craving to smoke’ [F(3, 
21)=3.29, p=.04], with significantly lower ratings following smoking OB [t(21)=5.34, 
p<.001] compared to pre-smoking ratings.  A relative difference between conditions was 
indicated on feeling ‘desire or craving to smoke’ [F(3, 20)=5.17, p=.008], with 
significantly lower ratings following OB (0.6) compared to EC nicotine levels of  0 (2.5), 
8 (1.9), or 16 mg/ml (2.0).  A main effect of condition was indicated on ‘coughing’ [F(3, 
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20)=3.11, p=.05], but there were no significant differences between conditions after 
correcting for multiple comparisons.  
QSU-B:  
Baseline Smoking and Deprivation Effects: On baseline days, ratings on nine of 
10 items of the 100-point QSU-B scale decreased after smoking OB.  The largest 
decreases were observed on ‘if it were possible I would probably smoke now,’ which 
decreased from 49.8 to 8.0 following smoking OB, and ‘’I am going to smoke as soon as 
possible,’ which decreased from 44.9 to 8.6 following smoking OB.  After 24-hours of 
tobacco deprivation, ratings on all variables of the QSU-B significantly increased.  All of 
these increases, except those reported for ‘smoking would make me less depressed,’ 
significantly exceeded ratings reported prior to smoking on baseline days.  The largest 
increases were observed on ‘if it were possible I would probably smoke now,’ which 
increased from 8.0 to 75.2 following 24-hours of tobacco deprivation, and ‘I am going to 
smoke as soon as possible,’ which increased from 8.6 to 69.8 following 24-hours of 
tobacco deprivation. 
Post-Deprivation OB or EC Effects:  A main effect of condition was observed on 
change in rating of ‘I have a desire for a cigarette right now’ [F(3, 21)=7.44, p=.001], 
with significantly lower ratings following smoking OB [t(21)=6.51, p<.001] compared to 
pre-smoking on deprivation days.  Comparable main effects of condition were observed 
on all other QSU-B variables except ‘nothing would be better than a cigarette right now,’ 
‘I could control things better right now if I could smoke,’ ‘I would do almost anything for 
a cigarette now,’ and ‘smoking would make me less depressed,’ which did not show 
significant changes following OB or EC use compared to levels prior to OB or EC use on 
26 
deprivation days.  Between conditions, on ‘I have a desire for a cigarette right now’ there 
were significantly lower ratings following OB (18.4) compared to EC nicotine levels of 0 
(58.4), 8 (50.4), or 16 mg/ml (56.4) (Figure 3f).  Although following OB or EC use, no 
condition was significantly lower than levels prior to OB or EC use on deprivation days, 
between conditions, on ‘nothing would be better than smoking a cigarette right now’ 
there were significantly lower ratings following OB (12.5) compared to EC with 0 (40.5), 
8 (36.8), or 16 mg/ml (39.9).  Between conditions, on ‘if it were possible I would 
probably smoke now’ there were significantly lower ratings following OB (13.8) 
compared to EC nicotine levels of 0 (65.8), 8 (55.1), or 16 mg/ml (57.3).  Between 
conditions, on ‘all I want right now is a cigarette’ there were significantly lower ratings 
following OB (15.9) compared to EC with nicotine levels of 0 (46.5) or 16 mg/ml 
(40.75).  Between conditions, on ‘I have an urge for a cigarette’ there were significantly 
lower ratings following OB (13.5) compared to EC with 0 (59.4), 8 (50.5), or 16 mg/ml 
(46.1).  Between conditions, on ‘a cigarette would taste good right now’ after OB or EC 
use [F(3, 21)=4.87, p=.01] there were significantly lower ratings following smoking OB 
[t(21)=5.77, p<.001] compared to pre-smoking on deprivation days.  Between conditions, 
on ‘a cigarette would taste good now’ there were significantly lower ratings following 
OB (17.1) compared to EC with nicotine levels of 0 (55.5), 8 (46.1), or 16 mg/ml (51.0).  
Between conditions, on ‘I am going to smoke as soon as possible’ there were 
significantly lower ratings following smoking OB [t(21)=5.00, p<.001] compared to pre-
smoking on deprivation days.  Between conditions, on ‘I am going to smoke as soon as 
possible’ [F(3, 20)=8.82, p=.006] there were significantly lower ratings following OB 
(18.5) compared to EC with nicotine levels of 0 (64.6), 8 (52.5), or 16 mg/ml (57.5).   
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HR and MAP: 
Baseline Smoking and Deprivation Effects: No significant changes in heart rate or 
mean arterial pressure were observed post OB smoking on baseline days.  Heart rate 
significantly decreased [t(7)=7.51, p<.001] from 84.0 bpm to 72.5 bpm after 24-hours of 
tobacco deprivation, which was significantly lower [t(7)=5.18, p=.001] than pre-smoking 
on baseline days.  Mean arterial pressure significantly decreased [t(7)=4.35, p=.003] from 
102.6 to 96.0 after 24-hours of tobacco deprivation, though this level was not 
significantly lower than pre-smoking levels on baseline days.   
Post-Deprivation OB or EC Effects:  A main effect of condition was observed on 
heart rate [F(3, 21)=3.45, p=.04], with significantly higher heart rate following OB 
[t(21)=4.95, p<.001] compared to pre-smoking on deprivation days.  A relative difference 
between conditions was indicated on heart rate [F(3, 20)=8.82, p=.006], with 
significantly greater heart rate following OB (90.1) compared to EC with nicotine levels 
of 16 mg/ml (75.0).   
VAS-Post Smoking:  
Post-Deprivation OB or EC Effects: A significant effect of condition was detected 
on ratings of ‘stimulated’ (Figure 3e) [F(3, 21)=4.52, p=.01] and ‘enjoy the e-cigarette’ 
[F(3, 21)=4.34, p=.02], with significantly higher ratings following OB compared to EC 
with 0 mg/ml.  Significant effects of condition were also detected on ratings of ‘like 
effects’ [F(3, 21)=5.23, p=.007] and ‘want to smoke again’ [F(3, 21)=11.82, p<.001], 
with significantly higher ratings following OB (68.2) compared to EC with nicotine 
levels of 0 (26.8), 8 (29.4), or 16 mg/ml (38.4) (Figure 3d).  A significant effect of 
condition was detected on ratings of ‘get pleasure from the e-cigarette’ [F(3, 21)=4.34, 
28 
p=.02], but there were no significant differences between conditions after correcting for 
multiple comparisons.     
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Table 3a. Demographic and Clinical Variables 
Total N = 8 
Gender 
     Female, N (%) 2 (25.0) 
Age, years (mean, SD) 34 ± 9.1 
Education, years (mean, SD) 14.4 ± 2.1 
Race 
     Caucasian, N (%) 
     Other, N (%) 
7 (87.5) 
1 (12.5) 
Fagerstrom Test for Nicotine Dependence Score, 
(mean, SD) 5.6 ± 2.1 
Tobacco, cigarettes per day (mean, SD) 19.7 ± 9.4 
Caffeine, days/week (mean, SD) 5.7 ± 2.6 
Alcohol, days/week (mean, SD) .82 ± .81 
Marijuana, occasions/month (mean, SD) .88 ± 1.6 
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   Table 3b. Cognitive, subjective, and physiological effects by session and condition 
Variable 
Baseline 
Smoking 24-Dep 
Baseline 
vs. 
24-Dep	  
Own 
Brand 
Electronic Cigarette Nicotine 
Concentrations 
0 mg/ml 8 mg/ml 16 mg/ml 
Rapid Information Processing Task 
       Digit rate !** 
       Reaction time on correct trials "* 
       Proportion correct !** 
       Commission errors 
Digit Symbol Substitution Task 
       Total trials completed !*  "* !** !** 
       Percentage trials correct 
Visual Analog Scale – Smoking effects !*  "  !** 
       Confused 
       Dizzy !* 
       Headache 
       Heart pounding !* "* 
       Lightheaded !** "** !*** 
       Nausea 
       Nervous 
       Salivation 
       Sweaty 
       Weak 
Minnesota Nicotine Withdrawal Scale 
       Angry, irritable, or frustrated  !*** !***	  
       Anxious or nervous 
       Depressed mood or sad  !* !*	  
       Desire or craving to smoke "***  !*** !*** "*** 
       Difficulty concentrating !** !**	  
       Increased appetite, hungry, or weight gain  !* !*	  
       Restless !* !*	  
       Impatient  !**  !**	  
       Constipated 
       Dizziness !* "* 
       Coughing  "* 
       Nauseous 
       Sore throat !*  "* 
Total Score !*** !***
Questionnaire of Smoking Urges – Brief
I have a desire for a cigarette right now "*** !*** !*** "***
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   Table 3b (continued). 
Baseline smoking = results of comparisons between pre- and post-smoking on baseline days.  24-Dep = results of comparisons between post-smoking on baseline 
days and prior to OB or EC use on deprivation days. Baseline vs. 24-Dep = results of comparisons between pre-smoking on baseline days and prior to OB or EC 
use on deprivation days.  Own brand and electronic cigarette nicotine concentration columns represent comparisons between condition and prior to OB or EC use 
on deprivation days.  *p≤.05, **p≤.01, ***p≤.001 
       Nothing would be better than smoking a cigarette    
       right now 
"***  !***  !**	  
       If it were possible I would probably smoke now "***  !***  !*** "*** 
       I could control things better right now if I could 
       smoke 
"** !** !*	  
       All I want right now is a cigarette "***  !***  !** "*** 
       I have an urge for a cigarette "*** !*** !*** "*** 
       A cigarette would taste good now "***  !***  !*** "*** 
       I would do almost anything for a cigarette now "**  !***  !**	  
     Smoking would make me less depressed !  * 
       I am going to smoke as soon as possible "***  !***  !**	    "*** 
Heart Rate and Blood Pressure 
       Heart rate "***  "** !*** 
       Mean arterial pressure  "** 
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Table 3c. Cognitive, subjective, and physiological effects of using electronic 
cigarettes compared to own brand cigarettes 
Variable	  
Electronic	  Cigarette	  Nicotine	  
Concentrations#	  
0	  mg/ml	   8	  mg/ml	   16	  mg/ml	  
Rapid	  Information	  Processing	  Task	  
	  	  	  	  	  	  	  Digit	  rate	  
	  	  	  	  	  	  	  Reaction	  time	  on	  correct	  trials	  
	  	  	  	  	  	  	  Proportion	  correct	  
	  	  	  	  	  	  	  Commission	  errors	  
Digit	  Symbol	  Substitution	  Task	  
	  	  	  	  	  	  	  Total	  trials	  completed	  
	  	  	  	  	  	  	  Percentage	  trials	  correct	  
Visual	  Analog	  Scale	  –	  Smoking	  effects	  
	  	  	  	  	  	  	  Confused	  
	  	  	  	  	  	  	  Dizzy	  
	  	  	  	  	  	  	  Headache	  
	  	  	  	  	  	  	  Heart	  pounding	  
	  	  	  	  	  	  	  Lightheaded	   !**	   !**	   !***	  
	  	  	  	  	  	  	  Nausea	  
	  	  	  	  	  	  	  Nervous	  
	  	  	  	  	  	  	  Salivation	  
	  	  	  	  	  	  	  Sweaty	  
	  	  	  	  	  	  	  Weak	  
Visual	  Analog	  Scale	  –	  Post	  Smoking	  
	  	  	  	  	  	  	  Stimulated	   !**	  
	  	  	  	  	  	  	  Like	  effects	   !**	   !**	   !**	  
	  	  	  	  	  	  	  Want	  to	  smoke	  again	   "***	   "***	   "***	  
	  	  	  	  	  	  	  Enjoy	  the	  e-­‐cigarette	   !**	  
	  	  	  	  	  	  	  Crave	  the	  e-­‐cigarette	  
	  	  	  	  	  	  	  Get	  pleasure	  from	  the	  e-­‐cigarette	  
Minnesota	  Nicotine	  Withdrawal	  Scale	  
	  	  	  	  	  	  	  Angry,	  irritable,	  or	  frustrated	  
	  	  	  	  	  	  	  Anxious	  or	  nervous	  
	  	  	  	  	  	  	  Depressed	  mood	  or	  sad	  
	  	  Desire	  or	  craving	  to	  smoke	   "**	   "**	   "***	  
	  	  	  	  	  	  	  Difficulty	  concentrating	  
	  	  	  	  	  	  	  Increased	  appetite,	  hungry,	  or	  weight	  gain	  
	  	  	  	  	  	  	  Restless	  
	  	  	  	  	  	  	  Impatient	  
	  	  	  	  	  	  	  Constipated	  
	  	  	  	  	  	  	  Dizziness	  
	  	  	  	  	  	  	  Coughing	  
	  	  	  	  	  	  	  Nauseous	  
	  	  	  	  	  	  	  Sore	  throat	  
	  	  	  	  	  	  	  Total	  Score	  
Questionnaire	  of	  Smoking	  Urges	  –	  Brief	  
	  	  	  	  	  	  	  I	  have	  a	  desire	  for	  a	  cigarette	  right	  now	   "***	   "***	   "***	  
	  	  	  	  	  	  	  Nothing	  would	  be	  better	  than	  smoking	  a	  cigarette	  right	  now	   "**	   "**	   "**	  
	  	  	  	  	  	  	  If	  it	  were	  possible	  I	  would	  probably	  smoke	  now	   "***	   "***	   "***	  
	  	  	  	  	  	  	  I	  could	  control	  things	  better	  right	  now	  if	  I	  could	  smoke	  
	  	  	  	  	  	  	  All	  I	  want	  right	  now	  is	  a	  cigarette	   "**	   "**	  
	  	  	  	  	  	  	  I	  have	  an	  urge	  for	  a	  cigarette	   "***	   "***	   "***	  
	  	  	  	  	  	  	  A	  cigarette	  would	  taste	  good	  now	   "**	   "**	   "**	  
	  	  	  	  	  	  	  I	  would	  do	  almost	  anything	  for	  a	  cigarette	  now	  
	  	  	  	  	  	  	  Smoking	  would	  make	  me	  less	  depressed	  
	  	  	  	  	  	  	  I	  am	  going	  to	  smoke	  as	  soon	  as	  possible	   "**	   "**	   "**	  
Heart	  Rate	  and	  Blood	  Pressure	  
	  	  	  	  	  	  	  Heart	  rate	   !**	  
	  	  	  	  	  	  	  Mean	  arterial	  pressure	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Table 3c. (continued) 
#: Comparison with Own Brand smoking condition.  Arrows represent values following EC use that were 
significantly above (") or below (!) values for own brand cigarettes following EC use on deprivation days; 
*p≤.05, **p≤.01, ***p≤.001
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Table 3d. Carbon monoxide levels for each participant 
Participant # 
Pre-smoking 
Baseline Days 
Pre-smoking 
Deprivation Days 
1 25.3 3.5 
2 26.0 4.3 
3 41.3 7.3 
4 61.3 5.5 
5 23.0 5.5 
6 35.5 6.5 
7 11.5 5.3 
8  9.8 6.0 
Total average 29.0 ± 18.3 5.5 ± 1.6 
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Figure 3a: Rapid Information Processing Task: Digit Rate 
Average number of digits presented per minute on the Rapid Information Processing Task.  After 24-hours of tobacco deprivation trial 
rate significantly increased [t(7) = 4.76, p =.002].  There were no statistically significant differences in trial rate following OB or EC 
use on baseline or deprivation days. 
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Figure 3b: Digit Symbol Substitution Task: Total Trials Completed Per Session 
Number of trials completed on the two-minute Digit Symbol Substitution Task.  A significant increase in total trials completed was 
observed following baseline smoking [t(7) = 2.37, p =.05] and a significant decrease was observed following 24-hour tobacco 
deprivation [t(7) = 3.22, p =.01].  Compared to levels prior to OB or EC use on deprivation days, there were significant increases in 
total trials completed following using electronic cigarettes dispensing vapor from the 8 mg/ml nicotine concentration [t(21) = 3.11, p 
=.005] or OB [t(21) = 2.85, p =.01].  
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Figure 3c: Self-report of “like effects” 
Self-report of “like effects” on a 100-point visual analog scale.  Following OB or EC use after 24-hours of tobacco deprivation, own 
brand cigarettes engendered significantly greater reports of ‘like effects’ compared to electronic cigarettes with 0 [t(21) = 3.56, p 
=.002], 8 [t(21) = 3.10, p =.005], or 16 mg/ml [t(21) = 2.89, p <.009]. 
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Figure 3d: Self-report of “want to smoke again?” 
Subjective ratings of “want to smoke again?” on a 100-point visual analog scale.  Following OB or EC use after 24-hours of tobacco 
deprivation, own brand cigarettes engendered significantly lower reports of ‘want to smoke again’ compared to electronic cigarettes 
with 0 [t(21) = 5.55, p <.001], 8 [t(12) = 4.19, p <.001], or 16 mg/ml [t(12) = 4.39, p <.001]. 
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Figure 3e: Self-report of feeling “stimulated” 
Subjective ratings of feeling “stimulated” on a 100-point visual analog scale.  Following OB or EC use after 24-hours of tobacco 
deprivation, own brand cigarettes engendered significantly greater reports of ‘stimulated’ compared to electronic cigarettes dispensing 
0 mg/ml nicotine [t(21) = 3.50, p =.002]. 
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Figure 3f: Self report of “I have a desire for a cigarette right now” 
Subjective ratings of “I have a desire for a cigarette right now” on a 100-point visual analog scale.  A significant decrease was 
observed following baseline smoking [t(7) = 7.45, p <.001] and a significant increased was observed following 24-hour tobacco 
deprivation [t(7) = 10.81, p <.001].  Levels prior to OB or EC use on deprivation days were significantly higher than pre-smoking 
levels on baseline days [t(7) = 5.71, p <.001].  Following OB or EC use on deprivation days, own brand cigarettes engendered 
significantly lower ratings compared to electronic cigarettes dispensing vapor from 0 [t(20) = 5.83, p <.001], 8 [t(20) = 4.73, p <.001], 
or 16 mg/ml [t(20) = 5.40, p <.001] nicotine concentrations.  
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CHAPTER FOUR: DISCUSSION 
Overall Conclusions 
self-
use
This study compared cognitive, self-reported, and physiological effects of a 
commercially available first-generation EC, with experimentally manipulated nicotine 
concentrations, to preferred brand CC’s in a sample of regular tobacco smokers, 
following 24-hours of tobacco deprivation.  Tobacco deprivation engendered typical 
self-report (MNWS and QSU-B) and physiological (heart rate) withdrawal symptoms.  
Smoking CC’s after 24-hours of tobacco deprivation ameliorated many of the self-report 
(e.g. six of 10 QSU-B items) and physiological effects (heart rate) associated with 
tobacco deprivation.  On all these measures of tobacco withdrawal, no attenuation of 
withdrawal effects from EC use was indicated.  On key abuse liability measures (e.g., 
liking), there were no significant changes from ratings prior to EC use following EC use 
(regardless of nicotine concentration), while OB smoking engendered significant 
changes on these ratings. 
Tobacco Withdrawal Symptoms
In order to assess tobacco withdrawal effects, participants were required to 
abstain from tobacco use for 24-hours prior to assessment of OB or EC use.  Baseline 
data were collected prior to tobacco deprivation in order to determine relative changes 
following typical smoking behaviors (unrestricted smoking) compared to smoking after 
24-hour tobacco abstinence.  Self-reported symptoms of withdrawal (MNWS and QSU-
B), exhaled CO levels, and heart rate all showed significant changes following 24-hour 
tobacco deprivation, which were commensurate with previous research on the effects of 
tobacco deprivation (e.g. Hughes and Hatsukami, 1986; Bell et al., 1999; Lee et al., 
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2011).  This verifies that the 24-hour deprivation period used in this study was effective 
at inducing tobacco withdrawal.   
Withdrawal effects were defined as measures that significantly changed from 
levels following smoking on baseline days to levels significantly different from pre-
smoking levels on baseline days after 24-hours of tobacco deprivation (e.g. heart rate).  
Acute effects were defined as measures that showed changes from pre- to post-smoking 
on baseline days and no significant deviation from pre-smoking levels on baseline days 
following 24-hours of tobacco deprivation.  For example, lightheadedness increased from 
pre- to post-smoking levels on baseline days, while returning to levels not significantly 
different from pre-smoking levels on baseline days following 24-hours of tobacco 
deprivation.  Similarly, total trials completed on the DSST increased following smoking 
on baseline days, while returning to levels that were not significantly different than pre-
smoking levels on baseline days following 24-hours of smoking deprivations.  On 
measures that followed this pattern, pre-smoking measurements on baseline days were 
compared to measurements after 24-hours of tobacco deprivation in order to determine if 
a withdrawal effect was present.  In accordance with this criteria, dizziness (on the VAS-
SE and MNWS), heart pounding, feeling lightheaded, sore throat, total trials completed 
on the DSST, and performance on the RIP were considered acute effects. 
Following 24-hour tobacco deprivation digit rate increased on the RIP, which was 
likely driven by an increase in proportion correct (because commission errors did not 
significantly change following 24-hour tobacco deprivation), while reaction time on 
correct trials on the RIP decreased.  There were no acute smoking effects on baseline 
days, which could suggest that changes in performance following 24-hour tobacco 
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deprivation on the RIP were due to tobacco withdrawal and not an acute effect.  Yet, 
since performance on the RIP prior to OB or EC use on deprivation days did not 
significantly differ from performance prior to smoking on baseline days, it could not be 
concluded that changes in RIP performance were due to tobacco deprivation.  There were 
also no significant changes in RIP performance following any the OB or EC conditions.  
This is incongruent with previous research reports showing changes in RIP performance 
following tobacco deprivation, and acute smoking of CC’s (e.g. Wesnes and Warburton, 
1984).  This might be due to the large variance in performance on this task not 
attributable to OB or EC condition (evident in Figure 3a).  Additionally, practice effects 
from multiple administrations of this task (before and after OB or EC use on baseline and 
deprivation days) may have confounded these results, such that clear effects of OB or EC 
use were not observable.  Since the primary purpose of this study was to examine 
management of withdrawal symptoms by EC’s compared to CC’s, we cannot make any 
conclusions about the ability of EC’s to manage cognitive withdrawal symptoms on this 
task due to a lack of a positive control.   
Number of trials completed on the DSST significantly decreased following 24-
hour tobacco deprivation but not relative to pre-smoking on baseline days.  This suggests 
an acute smoking effect, which was replicated on deprivation days following smoking 
OB.  Although there was a significant increase in total trials completed following 8 
mg/ml EC’s, Figure 3b demonstrates that performance following 8 mg/ml on deprivation 
days was actually decreased compared to other conditions.  A follow-up analysis of 
performance on deprivation days, prior using OB or EC, indicated that total trials 
completed on days prior to using an EC with 8 mg/ml was significantly lower than 
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compared to total trials completed preceding all other conditions.  Thus, this finding is 
likely a spurious result due to significantly lower performance on this measure prior to 
using an EC with 8 mg/ml days, and the lack of significant effects following 8 mg/ml on 
other measures employed in this study.  These results suggest that smoking OB may 
enhance cognitive performance on the DSST regardless of deprivation, while using an 
EC does not.  It has been suggested that changes in cognitive performance measured by 
laboratory tasks represents, in part, motivation for smoking, whereby use of tobacco 
could serve to enhance cognition (e.g., Evans and Drobes, 2009).  Performance on total 
trials completed on the DSST in the current study support this notion.  Since an acute 
effect of smoking OB was shown on the DSST, this might inform abuse liability rather 
than withdrawal management.  Thus, these results would suggest that EC’s have a lower 
abuse liability compared to CC’s with regards to their effects on DSST performance.  
Self-reported withdrawal effects were clearly indicated on several measures (i.e. 
seven items and total score on the MNWS, all QSU-B items).  This is consistent with 
previous research using these measures in populations of regular tobacco users who have 
undergone a period of tobacco deprivation (Teneggi et al., 2002; West and Ussher, 2009; 
Lee et al., 2011).  Following smoking OB, self-reported withdrawal symptoms on the 
QSU-B significantly decreased on baseline days (nine of 10 QSU-B items) and 
deprivation days (10 of 10 QSU-B items).  Reports of ‘desire or craving to smoke’ on the 
MNWS and six QSU-B items measured on deprivation days significantly decreased 
following smoking OB and not using EC’s, suggesting that EC’s are less effective than 
OB at managing self-reported withdrawal symptoms.  This evidence is consistent with 
previous studies that compared EC’s to a CC in tobacco deprived regular CC smokers 
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and found that EC’s were less effective than CC’s at reducing tobacco withdrawal 
symptoms (Vansickel et al., 2010; Bullen et al., 2010; Norton, June, and O’Connor, 
2014).  Results of the current study, however, also found that EC’s were unable to 
attenuate desires or cravings compared to pre-smoking levels, which is contrary to other 
studies that have shown some ability of EC’s to attenuate cigarette cravings in regular CC 
smokers (Vansickel et al., 2010; Bullen et al., 2010; Vansickel, Weaver, and Eissenberg, 
2012; Dawkins, Turner, and Crowe, 2013).  There are multiple possible explanations for 
this.  Relative to other studies, the current study used a longer period of tobacco 
deprivation, which may have yielded greater withdrawal effects that were more difficult 
to ameliorate with an EC.  There is also a possibility that the specific device used in the 
current study might have been less effective at reducing cigarette cravings.  For example, 
it has been demonstrated that EC’s release differing amounts of nicotine into vapor, 
regardless of the concentration of nicotine in their liquid (Goniewicz, Hajek, McRobbie, 
2014).  Thus, it could be that the EC used in this study was not as capable at delivering 
nicotine to the user as were devices used in other studies.  
Electronic Cigarettes and Abuse Liability 
Measures of liking (i.e. VAS-PS) were sensitive to smoking OB on baseline and 
deprivation days.  Participants rated OB significantly higher on ‘like effects’ compared to 
all nicotine concentrations of EC (Figure 3c), suggesting greater abuse liability for CC’s 
compared to the EC conditions tested in this study.  This is congruent with the only other 
studies that have compared EC’s to CC’s on some measure of liking (Vansickel et al., 
2010; Norton, June, and O’Connor, 2014).  Although to a lesser extent than CC’s, 
participants did endorse some liking for the EC (average of 31.5 across all EC nicotine 
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concentrations), which was independent of nicotine concentrations.  This suggests that 
EC’s have some abuse liability independent of nicotine concentrations, although to a 
lesser extent than CC’s.  Based on the absence of nicotine-concentration-related effects, it 
could be argued that this is because the EC provides some of the cues associated with CC 
smoking (e.g. tactile and visual similarity of the device, and similar inhalation behavior 
compared to CC’s), which are conditioned reinforcers due to a history of these stimuli 
being paired with nicotine delivered in CC’s.  If this were the case these, this might 
suggest that EC’s would have a lower abuse liability amongst individuals who have never 
used CC’s.  Yet, since this is the only study thus far to examine multiple nicotine 
concentrations administered with the same device, further research should confirm these 
findings before any firm conclusions are drawn.  
There were significant changes seen in heart rate following smoking OB, but not 
after smoking EC.  This is commensurate with some previous research on EC’s 
(Vansickel et al., 2010), yet inconsistent with other research (Vansickel, Weaver, and 
Eissenberg, 2012; Vansickel and Eissenberg, 2012).  Inconsistencies among studies with 
regards to heart rate changes following using EC’s might reflect variations in nicotine 
concentrations.  Exemplifying this, Yan and D’Ruiz (2015) found that heart rate 
significantly increased following ad-lib use of a Blu® EC with 24 mg/ml nicotine 
concentration, while there was no significant change in heart rate following use of a Blu® 
EC with 16 mg/ml nicotine concentration.  Furthermore, Yan and D’Ruiz (2015) found a 
positive correlation between plasma nicotine concentration and change in heart rate from 
before to after EC use.  This corroborates prior research, which has shown increases in 
heart rate following administration of nicotine via multiple routes of administration (e.g. 
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Benowitz et al., 1982; Henningfield, Miyasato, and Jasinski, 1985; Parrott and Winder, 
1989).  
The lack of ability of EC’s to alleviate withdrawal symptoms and reduced abuse 
liability compared to CC’s in this study, in conjunction with the absence of heart rate 
effects following use of an EC, might suggest a lack of significant nicotine delivery.  This 
would be congruent with a previous study that did not find significant elevations in 
plasma nicotine levels following 20-puffs from a first-generation EC with 16 or 18 mg/ml 
nicotine concentrations in a sample of EC naïve regular CC smokers (Vansickel et al., 
2010).  Vansickel and colleagues (2010) speculated that naivety to EC use might 
contribute to a lack of sufficient nicotine delivery.  This speculation was supported by a 
follow-up study by this group that demonstrated effective nicotine delivery in EC naïve 
CC smokers following four 10-puff bouts from a first-generation EC with 16 mg/ml 
nicotine concentration (Vansickel, Weaver, and Eissenberg, 2012).  Based on those 
findings, a comparable paced practice puffing procedure was incorporated into the design 
of the current study to increase the likelihood that participants would be sufficiently 
practiced to effectively use the EC.  These procedures would be expected to enhance the 
functional efficacy of EC’s relative to what would be encountered by smokers during 
initial exposure to EC’s in the natural ecology.  However, despite replicating the 
procedures demonstrated to be effective in the Vansickel et al (2012) study, the current 
study may not have been successful in training effective use of an EC, and insufficient 
levels of nicotine may have been delivered at even the highest nicotine concentration (16 
mg/ml) tested. In light of this possibility, future research on EC’s may want to 
incorporate procedures designed to verify nicotine delivery.   
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Limitations and Future Directions 
There are several limitations to the current study that must be acknowledged.  
First, although the device used in this study was chosen based on its popularity and wide 
availability, results taken from this device may not generalize to other brands or types 
(e.g. second- or third-generation) of EC’s.  Second, this study examined EC’s in 
individuals with minimal past EC experience.  This was done in order to examine 
processes associated with initial use of an EC among regular CC smokers.  Nonetheless, 
the effects reported in the current study may change as an individual gains more 
experience with an EC, as suggested by studies demonstrating that regular EC users are 
able to deliver behaviorally active nicotine doses (e.g. Yan and D’Ruiz, 2015).  Third, a 
paced puffing procedure was used in order to increase the likelihood of functional use of 
the EC among study participants.  Yet, it could be that more puffs are necessary to 
effectively deliver nicotine to the user (suggested by Vansickel, Weaver, and Eissenberg, 
2012).  Lastly, there may be individual differences that contribute to vulnerability to EC 
abuse liability, and by including subjects with prior but not current EC use individuals 
who were low in vulnerability to EC abuse may have been over-represented in this 
sample. 
Conclusion 
The current study demonstrated that, within the limitations of the nicotine 
concentrations that were tested and number of puffs administered, first-generation EC’s 
have no measurable efficacy in ameliorating tobacco withdrawal symptoms in regular CC 
smokers and are definitely not as effective as tobacco cigarette smoking.  Furthermore, 
measures of abuse liability suggest that while EC’s may have some abuse liability under 
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conditions of tobacco deprivation among regular tobacco smokers, the magnitude of the 
liability is clearly lower than that of CC’s.    
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